Trial of Cagrilintide for bone health in postmenopausal women
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether cagrilintide, a medicine similar to a natural hormone called amylin, can affect bone health. It is for postmenopausal women with obesity who do not have bone disease or other conditions affecting bone metabolism.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman past menopause (no period for at least 12 months).
- You are between 50 and 70 years old.
- Your body mass index (BMI) is 30 or higher.
- You do not have any bone disease (like osteoporosis or Paget’s disease).
- You do not have a condition that affects bone metabolism (like diabetes, thyroid problems, or celiac disease).
- You have not taken medications affecting bone metabolism (like bone-strengthening drugs, hormone therapy, or corticosteroids) in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called CagriSema to understand how it affects muscle health while helping people lose weight. You'll be in the trial for about a year, and researchers will monitor your muscle function and body composition.
This study compares two different versions of an investigational weight-loss medication (cagrilintide) against a placebo to see which is more effective and safe for people with excess weight. Participation involves receiving injections and regular check-ins to monitor your progress.
This early-stage study tests a new medication called cagrilintide to see how it influences appetite and food intake in adults with overweight or obesity. Researchers want to understand if this drug could help people feel fuller and eat less.
This study tests a new injectable medication called cagrilintide for people with obesity who had to stop GLP-1 drugs (like Ozempic or Wegovy) because of stomach problems. The goal is to see if cagrilintide causes fewer stomach side effects while still helping with weight.
This early-stage study tests different formulations of cagrilintide, a new medication, to see how the body absorbs and processes each version. Cagrilintide may help with weight management. Researchers will measure blood levels after you receive multiple doses.
This study tests how two medicines, cagrilintide and semaglutide, affect your metabolism compared to diet alone. It may help you understand how weight loss changes your body's energy use.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.